Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization
ConclusionsIn this large, diverse population of PLWH in the USA, the switch from TDF to TAF was associated with development of less favorable lipid profiles, regardless of pharmaco-enhancers or third-agent use. Statins remained underutilized after a switch from TDF to TAF. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 21, 2021 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
ConclusionsThe observed pharmacokinetics and pharmacodynamics were similar to reported data for non-Japanese healthy subjects, which support further evaluation of AZD5718 at similar doses/exposures in Japanese and non-Japanese subjects for future evaluation in patients with CAD and CKD. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 21, 2021 Category: Drugs & Pharmacology Source Type: research
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
ConclusionsObesity (BMI ≥ 30 kg/m2) negatively affects the clinical response of biological drugs in psoriatic patients, with anti-interleukin drugs being more affected by BMI than anti-tumor necrosis factor drugs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 18, 2021 Category: Drugs & Pharmacology Source Type: research
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
ConclusionsSacubitril-valsartan is cost effective in patients with acute decompensated heart failure. However, the results are highly dependent on the long-term cardiovascular mortality, and they are applicable only to Thailand or countries with a similarly structured healthcare system. Long-term registries should be pursued to decrease the uncertainty around long-term mortality. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 17, 2021 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain
ConclusionThe results of this pharmacoeconomic evaluation promote the use of tapentadol in comparison with oxycodone/naloxone, confirming the results obtained in previous studies with reference to the generic formulations. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 15, 2021 Category: Drugs & Pharmacology Source Type: research
Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?
ConclusionDaptomycin is likely less expensive and more effective than vancomycin or other initial regimens for MRSAB. More data are needed on the safety of linezolid against MRSAB. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 4, 2021 Category: Drugs & Pharmacology Source Type: research
The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia
ConclusionsPatients with antipsychotic dose reductions may be at risk for increased ER visits, increased hospitalizations, and significant unfavorable mental health-related clinical outcomes, suggesting that dose reduction may increase overall health care burden in some patients with schizophrenia. This work highlights the need for alternative strategies in the management of patients with TD. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 4, 2021 Category: Drugs & Pharmacology Source Type: research
Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia
AbstractStatins are currently the first-line drugs for managing dyslipidemia due to their substantial clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular disease (ASCVD). However, many patients do not reach their LDL-C target despite taking high-dose statins and some patients are intolerant of these drugs. Therefore, an additional or alternative pharmacological intervention may be required. Bempedoic acid is a novel lipid-lowering drug recently approved for the treatment of dyslipidemia. This review describes the pharmacology of bempedoic acid and its cli...
Source: Clinical Drug Investigation - August 25, 2021 Category: Drugs & Pharmacology Source Type: research
Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
ConclusionIn real-world settings in Greece, natalizumab displayed beneficial long-term effects on disease activity and disability progression consistent with previous studies with no new serious safety signals emerging. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 24, 2021 Category: Drugs & Pharmacology Source Type: research
Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal
We described the definition and reported clinical features of TSA/TSW including its classification into erythemato-edematous and papulopustular subtype. To assess the validity of TSA/TSW, we summarised and objectively appraised the postulated mechanisms for this condition, including tachyphylaxis, dysregulation of glucocorticoid receptors, rebound vasodilation and impaired skin barrier leading to a cytokine cascade. Understanding the evidence including its limitations and uncertainties highlights areas for future research and helps medical practitioners better counsel and provide care to patients who may be experiencing or...
Source: Clinical Drug Investigation - August 18, 2021 Category: Drugs & Pharmacology Source Type: research
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?
AbstractBreast cancer (BC) is the second most common tumour spreading to the central nervous system (CNS). The prognosis of patients with CNS metastases depends on several parameters including the molecular assessment of the disease. Although loco-regional treatment remains the best approach, systemic therapies are acquiring a role leading to remarkable long-lasting responses. The efficacy of these compounds diverges between tumours with different molecular assessments. Promising agents under investigation are drugs targeting the HER2 pathways such as tucatinib, neratinib, pyrotinib, trastuzumab deruxtecan. In addition, th...
Source: Clinical Drug Investigation - August 17, 2021 Category: Drugs & Pharmacology Source Type: research
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2 –3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience
ConclusionsThe increase of the Qalb values and the development of systemic OCBs in some SMA patients could be due to repeated lumbar puncture and to the immunogenic effect of nusinersen. On the other hand, the presence of OCBs in serum and/or CSF at baseline should be further investigated. Furthermore, biomarkers of neurodegeneration did not play a prognostic role in our cohort of adult SMA patients. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 13, 2021 Category: Drugs & Pharmacology Source Type: research
Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use
AbstractMoxetumomab pasudotox (Lumoxiti®), an anti-CD22 recombinant immunotoxin, is an important treatment option that is approved in adults with relapsed or refractory hairy cell leukaemia (HCL) who have received at least two prior lines of treatment with systemic therapies including purine nucleoside analogues. In a pivotal phase III trial, treatment with moxetumomab pasudotox resulted in approximately one third of patients achieving durable complete response lasting more than 6 months, as well as improvements in other haematological parameters and disease-related symptoms. Moxetumomab pasudotox had a generally manageab...
Source: Clinical Drug Investigation - August 12, 2021 Category: Drugs & Pharmacology Source Type: research
The Impact of Non-dopaminergic Medication on Quality of Life in Parkinson ’s Disease
ConclusionNon-dopaminergic drugs are frequently prescribed, and higher numbers are associated with impaired QoL in PD. However, when divided in drug types, only anti-epileptic drugs were negatively associated with QoL. In these patients, physicians might improve QoL by further optimizing the condition it was prescribed for (e.g., pain or anxiety), or managing of side effects.Trial registrationNetherlands Trial Register; NL4360. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 10, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy and Tolerability of Oral Compared with Sublingual Ketamine Lozenges as Rescue Analgesics in Adults for Acute Pain: The OSKet Trial
ConclusionsSublingual administration of ketamine led to a faster onset of pain relief (but also a higher adverse event rate), but in all other aspects treatment with ketamine given sublingually and orally produced similar analgesic effects.ACTRN: ACTRN12621000240842, 08/03/2021, retrospectively registered. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - August 8, 2021 Category: Drugs & Pharmacology Source Type: research
